Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: eico20 who wrote (1628)	1/13/2016 11:54:46 AM
From: eico20	Read Replies (1) \| Respond to of 2026

OK MI, so predicting clinical outcome of Fis. is critical, I think it will be positive, but you never know in these trials, TRT doesn't always show benefit in sexual function, I do like the show of confidence in this recent slide on evidence for Fis in sexual function: Prior studies conducted in hard to treat men (PDE failures) with erectile dysfunction show improvements in IIEF-EF at 300mg Fispemifene daily in conjunction with sildenafil ?Some sub-populations (men with diabetes) showed greater benefit Current Study: ?Dose at 450mg ?Broader patient population (including above populations) ?Lead-in designed to minimize placebo response/exclude placebo responders ?Additional supportive diaries (Sexual Encounter Profiles)